Skip to main content

Table 6 Estimated regional period parameters (T r ) for 2000 by cancer site and sex

From: Global and regional estimates of cancer mortality and incidence by site: I. Application of regional cancer survival model to estimate cancer mortality distribution by site

 

Oral

Oesophagus

Stomach

Colon and rectum

Liver

Pancreas

Region

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

AfrD

2.132

1.493

1.072

1.119

1.070

1.198

1.892

1.794

1.050

1.102

1.003

1.049

AfrE

2.111

1.486

1.065

1.117

1.069

1.195

1.880

1.784

1.050

1.101

1.003

1.048

AmrA

0.887

0.873

0.975

0.973

0.965

0.930

0.845

0.859

0.985

1.000

1.002

0.994

AmrB

1.747

1.357

1.017

1.087

1.047

1.140

1.663

1.590

1.046

1.080

1.003

1.037

AmrD

1.984

1.443

1.040

1.107

1.061

1.177

1.809

1.720

1.049

1.094

1.003

1.044

EmrB

1.774

1.368

1.019

1.089

1.049

1.144

1.681

1.606

1.046

1.082

1.003

1.038

EmrD

2.005

1.451

1.043

1.109

1.063

1.180

1.821

1.731

1.049

1.095

1.003

1.045

EurA

1.122

1.059

0.985

1.017

0.997

1.011

1.160

1.141

1.017

1.030

1.002

1.010

EurB1

1.797

1.376

1.021

1.091

1.050

1.148

1.695

1.618

1.047

1.083

1.003

1.038

EurB2

2.069

1.472

1.054

1.114

1.066

1.189

1.857

1.763

1.050

1.099

1.003

1.047

EurC

1.868

1.402

1.027

1.097

1.055

1.159

1.739

1.658

1.048

1.087

1.003

1.041

SearB

1.933

1.426

1.033

1.103

1.058

1.169

1.778

1.693

1.049

1.091

1.003

1.043

SearD

2.127

1.491

1.071

1.118

1.070

1.197

1.890

1.792

1.050

1.102

1.003

1.048

WprA

0.979

0.958

0.979

0.993

0.980

0.967

0.989

0.987

1.001

1.014

1.002

1.001

WprB1

1.990

1.445

1.041

1.108

1.062

1.178

1.812

1.723

1.049

1.095

1.003

1.044

WprB2

2.095

1.481

1.061

1.116

1.068

1.193

1.872

1.776

1.050

1.100

1.003

1.048

WprB3

1.967

1.437

1.038

1.106

1.060

1.174

1.799

1.711

1.049

1.093

1.003

1.044

 

Lung

Bladder

Non-Hodgkin lymphoma

Hodgkin lymphoma

Multiple myeloma

Leukaemia

Region

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

AfrD

1.141

1.212

3.526

2.844

1.466

1.581

2.176

2.419

1.081

1.213

1.539

1.493

AfrE

1.139

1.210

3.492

2.819

1.459

1.574

2.160

2.399

1.080

1.209

1.532

1.486

AmrA

0.984

0.995

0.493

0.653

0.891

0.913

0.676

0.557

0.945

0.907

0.880

0.875

AmrB

1.107

1.165

2.864

2.365

1.340

1.435

1.849

2.013

1.052

1.146

1.395

1.358

AmrD

1.129

1.195

3.284

2.669

1.420

1.528

2.057

2.271

1.070

1.188

1.487

1.444

EmrB

1.110

1.169

2.915

2.402

1.350

1.447

1.874

2.044

1.054

1.151

1.406

1.368

EmrD

1.131

1.198

3.320

2.695

1.427

1.536

2.075

2.293

1.072

1.192

1.494

1.451

EurA

1.031

1.061

1.405

1.312

1.064

1.114

1.127

1.117

0.986

0.999

1.078

1.061

EurB1

1.112

1.172

2.956

2.432

1.358

1.456

1.894

2.069

1.056

1.155

1.415

1.377

EurB2

1.136

1.205

3.424

2.771

1.447

1.559

2.126

2.357

1.077

1.203

1.517

1.472

EurC

1.118

1.181

3.083

2.524

1.382

1.484

1.957

2.148

1.061

1.168

1.443

1.403

SearB

1.124

1.189

3.197

2.606

1.403

1.509

2.014

2.217

1.067

1.180

1.468

1.426

SearD

1.141

1.212

3.519

2.839

1.464

1.580

2.173

2.415

1.081

1.212

1.538

1.492

WprA

1.006

1.025

0.908

0.953

0.970

1.004

0.881

0.812

0.964

0.949

0.970

0.959

WprB1

1.129

1.196

3.294

2.676

1.422

1.530

2.062

2.277

1.071

1.189

1.489

1.446

WprB2

1.138

1.208

3.468

2.802

1.455

1.569

2.148

2.384

1.079

1.207

1.527

1.481

WprB3

1.127

1.193

3.255

2.648

1.414

1.522

2.043

2.253

1.069

1.186

1.480

1.438

 

Melanoma

Miscellaneous

Breast

Cervix

Uterus

Ovary

Prostate

GDP Per capita

  

Region

Male

Female

Male

Female

Female

Female

Female

Female

Male

   

AfrD

3.811

6.596

1.720

1.741

2.748

1.647

1.896

1.261

5.559

1,158

  

AfrE

3.775

6.174

1.709

1.731

2.725

1.638

1.885

1.247

5.505

1,465

  

AmrA

0.452

0.819

0.718

0.849

0.657

0.845

0.881

1.064

0.647

28,910

  

AmrB

3.093

3.311

1.501

1.546

2.292

1.472

1.674

1.149

4.487

7,217

  

AmrD

3.550

4.680

1.640

1.670

2.582

1.583

1.815

1.196

5.168

3,367

  

EmrB

3.149

3.431

1.518

1.561

2.327

1.485

1.692

1.153

4.570

6,749

  

EmrD

3.589

4.864

1.652

1.680

2.606

1.592

1.827

1.202

5.226

3,040

  

EurA

1.481

1.431

1.019

1.117

1.286

1.086

1.186

1.085

2.125

20,562

  

EurB1

3.194

3.535

1.532

1.573

2.355

1.496

1.705

1.157

4.637

6,371

  

EurB2

3.702

5.541

1.687

1.711

2.678

1.620

1.862

1.225

5.395

2,085

  

EurC

3.332

3.897

1.574

1.611

2.443

1.530

1.748

1.169

4.843

5,206

  

SearB

3.455

4.297

1.611

1.644

2.521

1.560

1.786

1.183

5.027

4,168

  

SearD

3.804

6.506

1.718

1.739

2.744

1.645

1.894

1.258

5.549

1,218

  

WprA

0.922

1.072

0.855

0.971

0.943

0.954

1.020

1.073

1.319

25,115

  

WprB1

3.561

4.728

1.644

1.673

2.589

1.585

1.819

1.198

5.184

3,277

  

WprB2

3.749

5.920

1.701

1.724

2.708

1.631

1.877

1.238

5.466

1,688

  

WprB3

3.519

4.545

1.631

1.661

2.562

1.575

1.806

1.191

5.122

3,631

  
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us